Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Biotin Kit

August 11, 2010 8:33 am | Product Releases | Comments

Each HOOK Biotin kit is supplied with a biotin reagent, a specific Optimizer Buffer for enhanced conjugation, Spin-OUT columns for purification of labeled protein, and reagents to determine the amount of biotinylation.


Dilution Calculator

August 11, 2010 8:26 am | Product Releases | Comments

The oligo dilution calculator App from Eurofins MWG Operon is an innovative mobile solution to facilitate daily laboratory work. From now on, the determination of how much volume is needed to dilute an oligo stock solution can be done quickly at the bench.


Fluxion's IonFlux Wins R & D 100 Award

August 11, 2010 8:22 am | News | Comments

Fluxion Biosciences, a leading provider of functional cell analysis systems for drug discovery and diagnostics, announced that it has won a 2010 R&D 100 Award for its IonFlux HT System.


BMS Increases Commitment to ACTF

August 11, 2010 8:15 am | News | Comments

Bristol-Myers Squibb Company and the ADAP Crisis Task Force (ACTF) announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs (ADAPs) to provide antiretroviral medicines to people living with HIV and AIDS.


Researchers Closer to Understanding Cell Division

August 11, 2010 8:11 am | News | Comments

During cell division, microtubules emanating from each of the spindle poles meet and overlap in the spindle’s mid zone. Scientists at the European Molecular Biology Laboratory have uncovered the molecular mechanism that determines the extent of this overlap.


Cocaine Addiction Linked to Protein That Causes Retardation

August 11, 2010 8:03 am | News | Comments

Scientists from the Florida campus of The Scripps Research Institute have identified a protein that may act as the trigger controlling the addictive impact of cocaine in the brain.


Merck Buys Back One of Its Former Factories

August 11, 2010 7:58 am | by Linda A. Johnson | News | Comments

Drugmaker Merck & Co. has agreed to buy back a central Pennsylvania factory from the contract manufacturer that bought it 2 1/2 years ago.


New Superbug Gene Could Spread Widely

August 11, 2010 7:47 am | News | Comments

People getting cosmetic surgery in India have brought back to Britain a new gene that allows any bacteria to become a superbug, and scientists are warning this type of drug resistance could soon appear worldwide.


FDA Accepts Priority Review of XIFAXAN550

August 11, 2010 7:33 am | News | Comments

Salix Pharmaceuticals, Ltd. announced the U.S. Food and Drug Administration has accepted for priority review the company’s efficacy supplement to the new drug application for XIFAXAN 550 mg tablets for non-constipation irritable bowel syndrome and IBS-related bloating.


Valcyte Supplemental Approval Extends Treatment Time

August 11, 2010 7:27 am | News | Comments

Genentech, Inc. announced that the U.S. Food and Drug Administration approved increasing the length of therapy with Valcyte in adult kidney transplant patients at high risk for cytomegalovirus disease.


Immunomedics Granted Second CD74 Patent

August 11, 2010 7:24 am | News | Comments

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that a second patent has been granted for the CD74 target, stengthening the company's protection.


Shire Grants Noven Daytrana Marketing Rights

August 11, 2010 7:19 am | News | Comments

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana to Noven Pharmaceuticals, Inc. Daytrana is approved and marketed in the US for the treatment of attention deficit hyperactivity disorder in children and adolescents.


Alpharadin In Trial to Treat Bone Metastases

August 11, 2010 7:09 am | News | Comments

Algeta ASA, the focused oncology company, announces that it has treated the first patient in a phase 1/2a trial of Alpharadin in combination with docetaxel. The trial aims to recruit up to 60 men with bone metastases resulting from castration-resistant prostate cancer.


Marinomed Antiviral Spray Effective Against Colds

August 11, 2010 6:58 am | News | Comments

Marinomed Biotechnologie GmbH announced that a pilot clinical trial examining the company’s antiviral nasal spray, which contains carrageenan, was effective as a treatment against the common cold.


HemaQuest Begins Trial of EBV-Related Cancer Drug

August 11, 2010 6:53 am | News | Comments

HemaQuest Pharmaceuticals announced that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus infection.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.